Truist Financial Corp Sells 617 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Truist Financial Corp reduced its stake in shares of Exact Sciences Co. (NASDAQ:EXASGet Rating) by 3.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 18,461 shares of the medical research company’s stock after selling 617 shares during the period. Truist Financial Corp’s holdings in Exact Sciences were worth $600,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. American Century Companies Inc. lifted its stake in Exact Sciences by 16.5% in the first quarter. American Century Companies Inc. now owns 5,760 shares of the medical research company’s stock worth $403,000 after purchasing an additional 817 shares during the last quarter. MetLife Investment Management LLC bought a new stake in Exact Sciences in the first quarter worth $742,000. Panagora Asset Management Inc. raised its stake in shares of Exact Sciences by 4.6% during the first quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company’s stock valued at $509,000 after acquiring an additional 323 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Exact Sciences by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 448,640 shares of the medical research company’s stock valued at $31,377,000 after acquiring an additional 53,454 shares during the last quarter. Finally, Vontobel Holding Ltd. raised its stake in shares of Exact Sciences by 143.5% during the first quarter. Vontobel Holding Ltd. now owns 22,230 shares of the medical research company’s stock valued at $1,585,000 after acquiring an additional 13,102 shares during the last quarter. 90.30% of the stock is owned by institutional investors.

Analyst Ratings Changes

EXAS has been the subject of several recent analyst reports. Craig Hallum upped their price objective on shares of Exact Sciences from $35.00 to $44.00 in a research note on Monday, January 9th. Piper Sandler upped their price objective on shares of Exact Sciences from $40.00 to $50.00 and gave the company a “neutral” rating in a research note on Monday, November 14th. Citigroup reduced their price target on shares of Exact Sciences from $50.00 to $35.00 in a research report on Friday, November 4th. SVB Leerink boosted their price target on shares of Exact Sciences from $70.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, January 12th. Finally, BTIG Research reduced their price target on shares of Exact Sciences from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Monday, November 7th. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $61.57.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 1,000 shares of Exact Sciences stock in a transaction on Monday, January 9th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the executive vice president now owns 85,090 shares of the company’s stock, valued at approximately $5,105,400. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.30% of the company’s stock.

Exact Sciences Price Performance

Shares of EXAS opened at $68.23 on Monday. The stock has a market cap of $12.12 billion, a PE ratio of -16.64 and a beta of 1.30. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.20 and a current ratio of 2.47. Exact Sciences Co. has a fifty-two week low of $29.27 and a fifty-two week high of $84.31. The firm’s 50-day simple moving average is $50.46 and its two-hundred day simple moving average is $43.09.

Exact Sciences (NASDAQ:EXASGet Rating) last issued its earnings results on Thursday, November 3rd. The medical research company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.26. The firm had revenue of $523.07 million for the quarter, compared to the consensus estimate of $500.78 million. Exact Sciences had a negative net margin of 35.73% and a negative return on equity of 22.10%. Analysts anticipate that Exact Sciences Co. will post -3.69 earnings per share for the current fiscal year.

Exact Sciences Profile

(Get Rating)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Read More

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.